Activation of histone deacetylase 1 (hdac1) protects against...

Details Activation of histone deacetylase 1 (hdac1) protects against... Activation of histone deacetylase 1 (hdac1) protects against...

C - Chemistry, Metallurgy

07

D

C07D 493/04 (2006.01) A61K 31/122 (2006.01) A61K 31/137 (2006.01) A61K 31/16 (2006.01) A61K 31/198 (2006.01) A61K 31/24 (2006.01) A61K 31/35 (2006.01) A61K 31/352 (2006.01) A61K 31/55 (2006.01) A61K 31/662 (2006.01) A61K 31/663 (2006.01) A61K 31/675 (2006.01) A61P 25/14 (2006.01) A61P 25/28 (2006.01) C07C 215/58 (2006.01) C07C 233/56 (2006.01) C07D 223/16 (2006.01) C07D 311/30 (2006.01) C07C 229/36 (2006.01) C07F 9/30 (2006.01) C07F 9/38 (2006.01) C07F 9/59 (2006.01) C07F 9/62 (2006.01)

Patent

CA 2734991

The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+-)-4-amino-3-(5- chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)- SKF-81297, gambogic acid, and derivatives thereof.

L'invention porte sur des procédés et des composés destinés au traitement de troubles neurologiques, dont la maladie d'Alzheimer, la maladie de Parkinson, la maladie d'Huntington, la SLA (sclérose latérale amyotrophique), une lésion cérébrale traumatique, une lésion cérébrale ischémique ou un accident vasculaire cérébral. Dans un aspect, les composés sont des activateurs de HDAC1. Les activateurs de HDAC1 cités à titre dexemple comprennent les agents chélates de métaux, les agents chélates du fer, la déféroxamine, les flavonoïdes, les composés comprenant une fraction catéchol, la ginkgétine K, Chembridge 5104434, la sciadopilysine, l'acide tétrahydrogambogique, TAM-11, LY 235959, CGS 19755, SK&F 97541, l'acide étidronique, la lévonordefrine, la méthyldopa, l'ampicilline trihydratée, l'acide D-aspartique, l'acide gamma-D-glutamylaminométhylsulfonique, le chlorhydrate de phénazopyridine, le sel citrate d'oxalamine, la podophyllotoxine, SK&F 97541, l'acide (+-)-4-amino-3-5-chloro-2-thiényl)butanoïque, la (RS)-tétrazol-5-yl)glycine, R(+)-SKF-81297, l'acide gambogique et les dérivés de ceux-ci.

Affiliated with

Also associated with

Rating

Activation of histone deacetylase 1 (hdac1) protects against... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Activation of histone deacetylase 1 (hdac1) protects against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activation of histone deacetylase 1 (hdac1) protects against... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1361190